VCM
CLDX icon

Versant Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Versant Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6K Hold
689
– – ﹤0.01% 1811
2026
Q1 		$21.9K Buy
689
+37
+6% +$1.01K ﹤0.01% 1770
2025
Q4 		$17.7K Buy
652
+438
+205% +$11.5K ﹤0.01% 1718
2025
Q3 		$5.54K Hold
214
– – ﹤0.01% 2172
2025
Q2 		$4.36K Buy
214
+126
+143% +$2.45K ﹤0.01% 2206
2025
Q1 		$1.6K Buy
+88
New +$1.97K ﹤0.01% 2301
2024
Q4 		– Sell
-92
Closed -$3.13K – 2386
2024
Q3 		$3.13K Buy
+92
New +$3.5K ﹤0.01% 1432

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return